Scar - Pipeline Review, Q2 2011

Global Markets Direct, April 2011, Pages: 65

Scar - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Scar - Pipeline Review, Q2 2011', provides an overview of the Scar therapeutic pipeline. This report provides information on the therapeutic development for Scar, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Scar. 'Scar - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Scar.
- A review of the Scar products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Scar pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Scar.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Scar therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Scar Overview
Therapeutics Development
An Overview of Pipeline Products for Scar
Scar Therapeutics under Development by Companies
Scar Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Scar Therapeutics - Products under Development by Companies
Scar Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Scar Therapeutics Development
Allergan, Inc.
Halozyme Therapeutics
Renovo Group Plc
RXi Pharmaceuticals Corporation
CREABILIS Therapeutics S.r.l.
Graceway Pharmaceuticals, LLC
Excaliard Pharmaceuticals, Inc.
Beech Tree Labs, Inc.
Scar - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
EXC 001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HTI-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZX100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Juvista - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Juvista - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prevascar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXL01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RN1005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Activin-Like Kinase 5 Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Fibroblast Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Betamethason-17-valerat + Fusidic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Betamethason-17-valerat + Fusidic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DSC127 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT340 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alpha 2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TCA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Fibroblasts - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Scar Therapeutics – Drug Profile Updates
Scar - Featured News
Apr 04, 2011: Capstone Therapeutics Announces Update To Timing Of Release Of Final Results From AZX100 Phase IIa Pilot Clinical Trial In Surgical Scarring
Mar 03, 2011: Renovo Provides Update On Phase III Trial For Juvista
Feb 14, 2011: Pergamum To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions
Feb 11, 2011: Renovo Announces Results Of First EU Phase III Trial Of Juvista In Scar Revision Surgery
Feb 03, 2011: RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate
Jan 10, 2011: Excaliard Announces Positive Results From Three Phase II Trials For EXC 001
Dec 17, 2010: RXi Plans To Advance RXI-109 For Treatment Of Dermal Scarring
Dec 13, 2010: Capstone Reports Results From AZX100 Phase IIa Pilot Clinical Trials In Keloid And Surgical Scarring
Nov 23, 2010: Renovo Group Announces Successful Juvista Trial
Sep 13, 2010: Capstone Reports Progress In Phase IIa Clinical Trial Of AZX100 In Keloid Scarring
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Scar, Q2 2011
Products under Development for Scar – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Allergan, Inc., 2011
Halozyme Therapeutics, 2011
Renovo Group Plc, 2011
RXi Pharmaceuticals Corporation, 2011
CREABILIS Therapeutics S.r.l., 2011
Graceway Pharmaceuticals, LLC, 2011
Excaliard Pharmaceuticals, Inc., 2011
Beech Tree Labs, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Scar Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Scar, Q2 2011
Products under Development for Scar – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Sleep Disorders – Pipeline Review, H1 2013